

Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Independent Scientific Peer Review Panel Meeting

Assessing the Allergic Contact Dermatitis Potential of Chemicals and Products: Validation Status of New Versions and Applications of the Murine Local Lymph Node Assay (LLNA)

**Consumer Product Safety Commission Headquarters
Fourth Floor Hearing Room
Bethesda Towers Building 4330 East West Highway
Bethesda, MD**

Tuesday, March 4, 2008 - Thursday, March 6, 2008

TENTATIVE Agenda and Order of Business*

Tuesday, March 4, 2008

- 8:30 a.m. Opening Session**
- | | |
|--|------------------------------|
| Call to Order and Panel Introductions | Dr. Luster, Panel Chair |
| Welcome | Dr. Wind, ICCVAM Chair |
| Overview of ICCVAM Test Method | Dr. Stokes, NICEATM Director |
| Evaluation Process and Charge to the Panel | |
| Conflict of Interest Statements | Dr. Stokes |
| Overview of Agenda | Dr. Luster |
| Allergic Contact Dermatitis Current Regulatory Testing | Dr. Matheson, CPSC |
| Requirements and Hazard Classification Schemes | |
| The Traditional Murine LLNA Procedure | Dr. Matheson |
- The LLNA Limit Dose Procedure**
- Staff Presentation: Method Description and Overview
 - Panel Discussion
 - Public Comment Session: LLNA Limit Dose Procedure**
 - Action:** Panel Conclusions and Recommendations
- The Applicability Domain of the LLNA**
- Staff Presentation: Description and Overview of the draft Addendum
 - Panel Discussion
 - Public Comment Session: Applicability Domain of the LLNA**
 - Action:** Panel Conclusions and Recommendations
- 5:30 p.m. Adjourn for the Day**

** Note: This is a tentative schedule. The actual agenda may vary and it is possible that the panel may progress to the next topic earlier than scheduled, even if listed for the following day.*

Wednesday, March 5, 2008*

8:30 a.m. Call to Order and Introductions Dr. Luster

The LLNA: DA Method

Method Description and Overview Dr. Idehara, Daicel Chemical Industries
Staff Presentation: Overview of Draft Background Review Document
(BRD) and ICCVAM Recommendations
Panel Discussion
Public Comment Session: LLNA: DA Method
Action: Panel Conclusions and Recommendations

The LLNA: BrdU-FC Method

Method Description and Overview Dr. DeGeorge, MB Research Labs
Staff Presentation: Overview of Draft BRD and ICCVAM Recommendations
Panel Discussion
Public Comment Session: BrdU-FC Method
Action: Panel Conclusions and Recommendations

The LLNA: BrdU-ELISA Method

Method Description and Overview Dr. Takeyoshi, CERi - Japan
Staff Presentation: Overview of Draft BRD and ICCVAM Recommendations
Panel Discussion
Public Comment Session: BrdU-ELISA Method
Action: Panel Conclusions and Recommendations

5:30 p.m. Adjourn for the Day

Thursday, March 6, 2008*

8:30 a.m. Call to Order (10 min) Dr. Luster

Draft ICCVAM Performance Standards for LLNA

Staff Presentation of Draft Performance Standards
Panel Discussion
Public Comment Session: Draft ICCVAM Performance Standards for LLNA
Action: Panel Conclusions and Recommendations

The LLNA for Potency Determinations

Staff Presentation: Use of the LLNA for Assessing Potency
Categories for Skin Sensitization
Panel Discussion
Public Comment Session: Use of the LLNA for Potency Determinations
Action: Panel Conclusions and Recommendations

5:30 p.m. Adjourn

** Note: This is a tentative schedule. The actual agenda may vary and it is possible that the panel may progress to the next topic earlier than scheduled, even if listed for the following day.*